IDM PHARMA COMPLETES BONE CANCER TREATMENT TRIAL

Epimmune and IDM have announced the completion of their previously announced business combination and related transactions. The combined company, incorporated in Delaware and headquartered in San Diego, is named IDM Pharma. It is now a wholly owned French subsidiary of IDM. The company's lead product candidate, Junovan (formerly Mepact), has completed a Phase III clinical trial for the treatment of osteosarcoma. Junovan has received Orphan Drug Status in both the U.S. and the European Union. IDM Pharma is working with U.S. and EU regulatory agencies regarding the appropriate pathway for product marketing approval. IDM Pharma expects to receive regulatory approval for Junovan in the U.S. and the EU in 2007.